Your session is about to expire
← Back to Search
Methotrexate + Etoposide for Recurrent Brain Cancer
Study Summary
This trial is testing whether it is safe to give two cancer drugs at the same time to people with brain tumors that have come back.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 3 trial • 139 Patients • NCT02001987Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer started in the back part of my brain and has come back or gotten worse.I have recovered from side effects of my previous cancer treatments.My blood tests show enough neutrophils, platelets, and hemoglobin.I am mostly active and can do things for myself.My neurological symptoms have been stable for at least a week.I haven't had any experimental treatments or chemotherapy within the last week.I had my last cancer treatment at least a week ago.I am between 1 and 80 years old and my cancer has come back or gotten worse.I have or agree to get a special device implanted for my brain tumor treatment.
- Group 1: Methotrexate / Etoposide Infusion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are individuals past the age of 55 eligible to participate in this experiment?
"All participants in this medical trial must meet the age requirement of at least 1 year old and not exceed 80 years."
Is the recruitment phase of this experiment ongoing?
"Affirmative. According to the details hosted on clinicaltrials.gov, this medical trial is currently enlisting participants. It was initially published on October 1st 2016 and its most recent update occurred on August 17th 2022. There is a requirement for 10 patients at one site in particular."
Which individuals have the criteria to participate in this experiment?
"This clinical trial is enlisting 10 individuals with recurrence, ranging in age from 1 year to 80. Necessary qualifications for enrolment include: A one week gap between the conclusion of systemic chemotherapy and/or radiation therapy and start of intracavitary treatment; a Lansky score or Karnofsky score of 50 or greater depending on their age; recovery from prior anticancer medications' adverse effects; an already-implanted catheter connected to an Ommaya reservoir (or agreement to get one installed); neurological stability over the past 7 days; life expectancy of at least three months as determined by the Principal Investigator (PI);"
How many participants have been recruited into the experiment thus far?
"Affirmative. The clinicaltrials.gov website suggests that the trial is still in search of participants, having first been posted on October 1st 2016 and last modified on August 17th 2022. In total, 10 patients are needed to participate from a single medical site."
Are there any additional investigations involving Methotrexate?
"Currently, there are 486 ongoing clinical trials examining the efficacy of Methotrexate. Of those studies, 135 have advanced to Phase 3 testing. Notably, while Seattle is a hub for research on this treatment, it is being researched in 19,513 locations worldwide."
What conditions can Methotrexate typically be administered to address?
"Generally employed to treat bladder cancer, methotrexate can also be beneficial in managing conditions such as merkel cell carcinoma, meningeal leukemia and prostate cancer."
Share this study with friends
Copy Link
Messenger